MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/leu.2017.303

Медицинская библиотека · Leukemia · 2017

RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.

Jerchel I S, Hoogkamer A Q, Ariës I M, Steeghs E M P, Boer J M, Besselink N J M, Boeree A, van de Ven C, de Groot-Kruseman H A, de Haas V, Horstmann M A, Escherich G, Zwaan C M, Cuppen E, Koudijs M J, Pieters R, den Boer M L

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

RAS pathway mutations have been linked to relapse and chemotherapy resistance in pediatric B-cell precursor acute lymphoblastic leukemia (BCP-ALL). However, comprehensive data on the frequency and prognostic value of subclonal mutations in well-defined subgroups using highly sensitive and quantitative methods are lacking. Targeted deep sequencing of 13 RAS pathway genes was performed in 461 pediatric BCP-ALL cases at initial diagnosis and in 19 diagnosis-relapse pairs. Mutations were present in 44.2% of patients, with 24.1% carrying a clonal mutation. Mutation frequencies were highest in high hyperdiploid, infant t(4;11)-rearranged, BCR-ABL1-like and B-other cases (50-70%), whereas mutations were less frequent in ETV6-RUNX1-rearranged, and rare in TCF3-PBX1- and BCR-ABL1-rearranged cases (27-4%). RAS pathway-mutated cells were more resistant to prednisolone and vincristine ex vivo. Clonal, but not subclonal, mutations were linked to unfavorable outcome in standard- and high-risk-treated patients. At relapse, most RAS pathway mutations were clonal (9 of 10). RAS mutant cells were sensitive to the MEK inhibitor trametinib ex vivo, and trametinib sensitized resistant cells to prednisolone. We conclude that RAS pathway mutations are frequent, and that clonal, but not subclonal, mutations are associated with unfavorable risk parameters in newly diagnosed pediatric BCP-ALL. These mutations may designate patients eligible for MEK inhibitor treatment.

Для цитирования: Jerchel I S, Hoogkamer A Q, Ariës I M, Steeghs E M P, Boer J M, Besselink N J M, Boeree A, van de Ven C, de Groot-Kruseman H A, de Haas V, Horstmann M A, Escherich G, Zwaan C M, Cuppen E, Koudijs M J, Pieters R, den Boer M L. RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia.. Leukemia. 2017. DOI: 10.1038/leu.2017.303.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.